These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9753265)

  • 1. Esophageal irritation due to alendronate sodium tablets: possible mechanisms.
    Peter CP; Handt LK; Smith SM
    Dig Dis Sci; 1998 Sep; 43(9):1998-2002. PubMed ID: 9753265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Esophageal lesions associated with diphosphonates].
    Larsen KO; Stray N; Engh V; Sandnes D
    Tidsskr Nor Laegeforen; 2000 Aug; 120(20):2397-9. PubMed ID: 11475224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
    Lanza FL; Hunt RH; Thomson AB; Provenza JM; Blank MA
    Gastroenterology; 2000 Sep; 119(3):631-8. PubMed ID: 10982755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.
    Graham DY
    Dig Dis Sci; 2002 Aug; 47(8):1665-78. PubMed ID: 12184516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate.
    Shakweh M; Bravo-Osuna I; Ponchel G
    Eur J Pharm Sci; 2007 Aug; 31(5):262-70. PubMed ID: 17576054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alendronate-induced severe esophagitis. A rare and severe reversible side-effect illustrated by three case reports].
    Tóth E; Fork FT; Lindelöw K; Lindström E; Verbaan H; Veress B
    Lakartidningen; 1998 Aug; 95(35):3676-80. PubMed ID: 9748782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of pH-responsive alginate raft formulation of risedronate for reduced esophageal irritation.
    Jang SW; Lee JW; Ryu DS; Son M; Kang MJ
    Int J Biol Macromol; 2014 Sep; 70():174-8. PubMed ID: 24995633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
    Dansereau RJ; Crail DJ; Perkins AC
    Curr Med Res Opin; 2008 Apr; 24(4):1137-45. PubMed ID: 18334082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate-associated esophageal injury: pathologic and endoscopic features.
    Abraham SC; Cruz-Correa M; Lee LA; Yardley JH; Wu TT
    Mod Pathol; 1999 Dec; 12(12):1152-7. PubMed ID: 10619269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats.
    Peter CP; Kindt MV; Majka JA
    Dig Dis Sci; 1998 May; 43(5):1009-15. PubMed ID: 9590415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 12. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
    Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
    Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate mucosal injury--the end of the story?
    Lanza F
    Dig Liver Dis; 2003 Feb; 35(2):67-70. PubMed ID: 12747621
    [No Abstract]   [Full Text] [Related]  

  • 14. Physiological and morphological effects of alendronate on rabbit esophageal epithelium.
    Dobrucali A; Tobey NA; Awayda MS; Argote C; Abdulnour-Nakhoul S; Shao W; Orlando RC
    Am J Physiol Gastrointest Liver Physiol; 2002 Sep; 283(3):G576-86. PubMed ID: 12181170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water.
    Perkins AC; Wilson CG; Frier M; Blackshaw PE; Dansereau RJ; Vincent RM; Wenderoth D; Hathaway S; Li Z; Spiller RC
    Int J Pharm; 2001 Jul; 222(2):295-303. PubMed ID: 11427359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
    Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
    Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
    Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
    J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bisphosphonates for osteoporosis].
    Narusawa K; Nakamura T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa.
    Lichtenberger LM; Romero JJ; Gibson GW; Blank MA
    Dig Dis Sci; 2000 Sep; 45(9):1792-801. PubMed ID: 11052322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw: new developments in an old disease.
    Khan A
    J Rheumatol; 2008 Apr; 35(4):547-9. PubMed ID: 18398947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.